Evidence map›Paper›PMID 42963368›Full record

ArticleMolecular psychiatry2026

Identification of fluid endocannabinoid and sphingolipid biomarkers in schizophrenia. A machine learning approach toward clinical value.

Anna E Hoffmann, Michael Allwright, Boris Guennewig, Cathrin Rohleder, Beverly Jieu, Dagmar Koethe, Inga Dammann, Andrea Arroyo Del Castillo, Juliane K Mueller, Frank Enning and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anna E HoffmannBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0009-0008-7263-8907
Michael AllwrightForeFront, Brain and Mind Centre, The University of Sydney, Sydney, Australia.
Boris GuennewigForeFront, Brain and Mind Centre, The University of Sydney, Sydney, Australia.
Cathrin RohlederBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-3559-1846
Beverly JieuBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Dagmar KoetheBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Inga DammannEndosane Pharmaceuticals GmbH, Berlin, Germany.
Andrea Arroyo Del CastilloDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Juliane K MuellerDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Frank EnningDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0002-3577-2778
Claire E ShepherdNeuroscience Research Australia, Randwick, Australia.ORCID http://orcid.org/0000-0002-0399-3218
Timothy A Couttas *Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. t.couttas@neura.edu.au.ORCID http://orcid.org/0000-0002-5896-2638
F Markus Leweke *Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-8163-195X

Funding

Stanley Medical Research Institute (SMRI) 03-NV-003
6 · The paper itself

Abstract

Schizophrenia (SCZ) diagnosis relies on subjective clinical evaluation, with symptoms often overlapping between psychiatric conditions, hindering early intervention, and creating an urgent need for objective, accessible biomarkers. Lipids, especially endocannabinoid system (ECS) and sphingolipid metabolism members, are promising candidates given their implication in SCZ pathogenesis and measurability in accessible biofluids, with minimally invasive procedures. Our study conducted the first comprehensive crossover of endocannabinoids (eCBs) and sphingolipids in matched cerebrospinal fluid (CSF) and serum samples from antipsychotic-naïve SCZ patients (SCZ

Identifiers

PMID42963368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.